Key points from article :
Researchers commonly determine the presence of senescent cells through the use of the p16ink4a (p16) and ?-galactosidase biomarkers.
May not be the only cells that exhibit both of these biomarkers.
Therapies target these too, removing cells that are not senescent.
Oisin Biotechnology does use p16 as a target biomarker.
Benefits may outweigh risk of removing non-senescent cells.
The studies were published in the Aging and Nature journals.
